Lütt, A.
Tsamitros, N.
Wolbers, T.
Rosenthal, A.
Bröcker, A. L.
Schöneck, R.
Bermpohl, F.
Heinz, A.
Beck, A.
Gutwinski, S.
Funding for this research was provided by:
Berlin Institute of Health
Deutsche Forschungsgemeinschaft (Project-ID 402170461 – TRR 265, Project-ID 402170461 – TRR 265, Project-ID 402170461 – TRR 265)
Charité - Universitätsmedizin Berlin
Article History
Received: 16 June 2023
Accepted: 3 November 2023
First Online: 14 November 2023
Declarations
:
: This study was approved by the Charité Universitätsmedizin Berlin Institutional Review Board (EA1/190/22, 23.05.2023). Informed consent will be obtained from all subjects. Minors or persons unable to consent will not be included. All research is carried out in accordance with the Declaration of Helsinki, data protection laws and good clinical practice (GCP) as well as other relevant guidelines and regulations.
: Not applicable.
: PD Dr. Gutwinski, Prof. Beck, Mr. Tsamitros and Dr. Lütt cooperate with neomento GmbH without financial interests for the development of the VR software for VirtuCueR, a VR treatment for patients with alcohol use disorder, currently developed and supported by the BIH Digital Health Accelerator. Prof. Wolbers works as Chief Science Officer for neomento GmbH. All other authors have no competing interest to declare.